Clinical Trials · NCT05579977

Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity

Name: Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

TerminatedPhase 2Semaglutide

Phase: Phase 2
Recruitment status: Terminated
Sponsor: Pfizer
Enrollment: 902
Start date: Oct 2022
Locations: 90 sites, 8 countries
Primary endpoint: Placebo-adjusted, Change From Baseline in Percentage of Glycated Hemoglobin (HbA1c) at Week 32: Cohort 1 (Type 2 Diabetes Mellitus)

View Semaglutide compound reference